166 related articles for article (PubMed ID: 38156112)
1. Editorial: Challenges in peripheral T-cell lymphomas: from biological advances to clinical applicability.
Lage LAPC; Pereira J; Wilcox RA
Front Oncol; 2023; 13():1325170. PubMed ID: 38156112
[No Abstract] [Full Text] [Related]
2. Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability.
Zain J; Kallam A
Front Oncol; 2023; 13():1150715. PubMed ID: 37188189
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
4. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up.
Vega F; Amador C; Chadburn A; Hsi ED; Slack G; Medeiros LJ; Feldman AL
Mod Pathol; 2022 Mar; 35(3):306-318. PubMed ID: 34584212
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into the pathogenesis of T-cell lymphomas.
Van Arnam JS; Lim MS; Elenitoba-Johnson KSJ
Blood; 2018 May; 131(21):2320-2330. PubMed ID: 29666117
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii.
Cheson BD; Horwitz SM; Weisenburger DD
Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 26):1-14; quiz 15-6. PubMed ID: 22362328
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
8. Biological insights into the role of TET2 in T cell lymphomas.
Carty SA
Front Oncol; 2023; 13():1199108. PubMed ID: 37841428
[TBL] [Abstract][Full Text] [Related]
9. The applicability of the new WHO-EORTC classification of primary cutaneous lymphomas to a single referral center.
Khamaysi Z; Ben-Arieh Y; Izhak OB; Epelbaum R; Dann EJ; Bergman R
Am J Dermatopathol; 2008 Feb; 30(1):37-44. PubMed ID: 18212543
[TBL] [Abstract][Full Text] [Related]
10. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
Chung C
J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop.
Climent F; Nicolae A; de Leval L; Dirnhofer S; Leoncini L; Ondrejka SL; Soma L; Wotherspoon A; Zamo A; Quintanilla-Martinez L; Ng SB
Virchows Arch; 2023 Sep; 483(3):333-348. PubMed ID: 37646869
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas.
Yoon SE; Cho J; Kim YJ; Ko YH; Park WY; Kim SJ; Kim WS
Exp Hematol Oncol; 2021 May; 10(1):33. PubMed ID: 33990228
[TBL] [Abstract][Full Text] [Related]
13. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetic regulators in the treatment of T-cell lymphoma.
Ahmed N; Feldman AL
Expert Rev Hematol; 2020 Feb; 13(2):127-139. PubMed ID: 31903826
[No Abstract] [Full Text] [Related]
15. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
16. Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay.
Drieux F; Ruminy P; Abdel-Sater A; Lemonnier F; Viailly PJ; Fataccioli V; Marchand V; Bisig B; Letourneau A; Parrens M; Bossard C; Bruneau J; Dobay P; Veresezan L; Dupuy A; Pujals A; Robe C; Sako N; Copie-Bergman C; Delfau-Larue MH; Picquenot JM; Tilly H; Delarue R; Jardin F; de Leval L; Gaulard P
Haematologica; 2020 Jun; 105(6):1582-1592. PubMed ID: 31488561
[TBL] [Abstract][Full Text] [Related]
17. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls.
Jaffe ES; Nicolae A; Pittaluga S
Mod Pathol; 2013 Jan; 26 Suppl 1(Suppl 1):S71-87. PubMed ID: 23281437
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma.
Stuver R; Moskowitz AJ
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765544
[TBL] [Abstract][Full Text] [Related]
20. Biological and clinical significance of epigenetic alterations in B-cell lymphomas.
Ennishi D
Int J Hematol; 2022 Dec; 116(6):821-827. PubMed ID: 36208393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
